AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/19/20

Image source: The Motley Fool. Aurinia Pharmaceuticals Inc    (NASDAQ: AUPH) Q1 2020 Earnings Call May. 14, 2020 , 2:30 p.m. ET Operator Continue reading

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 RBC Capital Markets’ Virtual Global Healthcare Conference on ...

Aurinia Pharmaceuticals, Inc. (AUPH) Q1 2020 Earnings Conference Call May 14, 2020, 16:30 ET Company Participants Glenn Schulman - SVP, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Neil Solomons - Chief Medical Officer Max Colao - Chief Comm...

Aurinia Pharma (NASDAQ: AUPH ): Q1 GAAP EPS of -$0.15 beats by $0.12 . Revenue of $0.03M (flat Y/Y) misses by $0.02M . Cash and equivalents of $286.1M. Press Release More news on: Aurinia Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news,

- Cash and cash equivalents totaled approximately $286 million at March 31, 2020 - - Rolling submission of voclosporin New Drug Application to the U.S. Food & Drug Administration remains on track for completion by the end of the second quarter 2020 – - Continued evolut...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that it will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the markets close. Aurinia’s management team will host a conference call to discuss the Comp...

Aurinia Pharmaceuticals (AUP CN) initiated with Outperform rating and C$30 (29% upside) price target at Cowen and Company. No premarket activity yet (NASDAQ: AUPH ) in U.S. More news on: Aurinia Pharmaceuticals Inc., Blueprint Medicines Corporation, Cytokinetics, Incorporated, Healthcare s...

- Dennis Bourgeault to retire after more than 20 years with the company - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indicati...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the appointment of Timothy P. Walbert, chairman, president a...

Investing in biotech stocks can feel like a rollercoaster ride. Positive clinical trial results, drug approvals, or lucrative partnership announcements can send stocks soaring. These stocks can just as easily get eviscerated on drug failures, regulatory setbacks, and patent challenges. To rais...